Vorinostat and Palliative Radiotherapy - Full Text View

Vorinostat and Palliative Radiotherapy (PRAVO)

This study has been completed.

First Received on April 2, 2007. Last Updated on July 21, 2011 History of Changes

Sponsor:	Oslo University Hospital
Information provided by:	Oslo University Hospital
ClinicalTrials.gov Identifier:	NCT00455351

Purpose

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Condition	Intervention	Phase
Pelvic Cancer Radiotherapy	Drug: Vorinostat	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.

Resource links provided by NLM:

MedlinePlus related topics: Cancer

Drug Information available for: Vorinostat

U.S. FDA Resources

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:

Arms	Assigned Interventions
Experimental: A I Study drug	Drug: Vorinostat Increasing dosing, phase I

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00455351

Locations

Norway
The Norwegian Radium Hospital
Oslo, Norway, NO-0310

Sponsors and Collaborators

Oslo University Hospital

Investigators

Study Director:

Sigbjørn Smeland, MD,PhD

The Norwegian Radium Hospital

More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party:	Svein Dueland (PI), Rikshospitalet-Radiumhospitalet HF
ClinicalTrials.gov Identifier:	NCT00455351 History of Changes
Other Study ID Numbers:	EudraCTnumber 2006-003631-76
Study First Received:	April 2, 2007
Last Updated:	July 21, 2011
Health Authority:	Norway: Norwegian Medicines Agency

Keywords provided by Oslo University Hospital:

Palliative treatment
Max. tolerable dose

Additional relevant MeSH terms:

Pelvic Neoplasms
Neoplasms by Site
Neoplasms
Vorinostat
Histone Deacetylase Inhibitors

Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 22, 2012